Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant Cymbalta lost patent protection and faced competition from less-expensive generics. Lilly said its revenue from Cymbalta plunged 73%t and revenue from the osteoporosis treatment Evista fell 65%.
The company reported net product sales of Soliris® (eculizumab) of $555.1 million in the third...
For all the strengths of Texas Health Presbyterian Hospital Dallas, the first U.S.-diagnosed...
New federal Ebola response squads — likened to public health SWAT teams — are being readied to rush to any U.S. city where a new Ebola case might be identified, officials say.
The EMA has established a form of rolling review that allows experts to continuously assess incoming data and develop increasingly robust scientific opinions based on the additional data provided during the process. The initial review and subsequent updates will be shared with healthcare decision-makers in the most affected and other countries.
The City of Dallas released new video of Bentley, who was quarantined when his owner was diagnosed with Ebola. Officials say he still tests negative.
Researchers in Chicago say that an experimental cancer drug is showing promise. Also, a new risk for bariatric surgery recipients.
Researchers at Harvard found that two-thirds of dietary supplements that have previously been recalled still contain banned ingredients. Also, smoking may get in the way of recovering alcoholics.
Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire AgreementOctober 23, 2014 10:31 am | News | Comments
The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, using Sutro’s cell-free biologics development platforms. During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms.
The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.
Children showing improvements with new "video therapy" treatment.
The indictment alleges that two Louisiana workers in St. John the Baptist Parish didn't test water samples assigned to them.
HealthCare.gov's new EZ application for coverage can't be used by legal immigrants or naturalized U.S. citizens, prompting concern that many Hispanics and Asians will go right back into long enrollment queues this year.
Most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient, according to an Associated Press-GfK poll.
Vaxart, a privately held company developing vaccines that are administered by tablet rather than by injection, today announced that the company is accelerating its Ebola tablet vaccine program. Following a recent meeting with the FDA, Vaxart anticipates commencing human clinical trials in the first quarter of 2015.
The companies announced a team-up in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375M in milestones and other payments.
Announcing the availability of three new chromatography resins for Chromabolt® prepacked columns.
Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the U.S. from Ebola-stricken nations will be monitored for symptoms for 21 days. That includes returning American aid workers, federal health employees and journalists, as well as West African travelers.